Rockwell Medical Looks Like A Speculative Buy As It Approaches Profitability
Rockwell is a microcap manufacturer of hemodialysis concentrates for kidney failure patients, trading at under 1x full-year 2023 revenue. The company has a significant market opportunity with the growing number of kidney failure patients and potential for expansion into the home dialysis market. Despite a discounted valuation, Rockwell's growth trajectory, focus on profitability, and management execution make it a compelling investment with substantial upside potential.
Rockwell Medical, Inc. (NASDAQ:RMTI) Expected to Post Q2 2024 Earnings of ($0.04) Per Share
Rockwell Medical, Inc. (NASDAQ:RMTI – Free Report) – Research analysts at HC Wainwright lowered their Q2 2024 EPS estimates for shares of Rockwell Medical in a report released on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.04) for the quarter, down from their prior forecast of ($0.03). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at ($0.02) EPS and FY2024 earnings at ($0.14) EPS. Rockwell Medical (NASDAQ:RMTI – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Rockwell Medical had a negative net margin of 9.72% and a negative return on equity of 28.29%. The firm had revenue of $22.68 million for the quarter, compared to the consensus estimate of $21.18 million. During the same period last year, the firm posted ($0.10) EPS. Separately, StockNews.com cut shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Friday. Read Our Latest Research Report on RMTI Rockwell Medical Stock Up 1.4 % RMTI stock opened at $1.77 on Monday. Rockwell Medical has a one year low of $1.16 and a one year high of $6.24. The stock has a market capitalization of $53.51 million, a PE ratio of -4.90 and a beta of 1.21. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.38 and a current ratio of 1.79. The company has a fifty day moving average of $1.58 and a 200-day moving average of $1.61. Institutional Trading of Rockwell Medical Several hedge funds and other institutional investors have recently made changes to their positions in RMTI. Armistice Capital LLC raised its position in Rockwell Medical by 631.7% during the third quarter. Armistice Capital LLC now owns 2,817,000 shares of the company’s stock worth $5,859,000 after acquiring an additional 2,432,000 shares during the last quarter. Perkins Capital Management Inc. grew its holdings in shares of Rockwell Medical by 366.3% during the fourth quarter. Perkins Capital Management Inc. now owns 349,934 shares of the company’s stock worth $661,000 after buying an additional 274,891 shares in the last quarter. Raymond James & Associates grew its holdings in shares of Rockwell Medical by 298.7% during the third quarter. Raymond James & Associates now owns 190,670 shares of the company’s stock worth $397,000 after buying an additional 142,850 shares in the last quarter. ClariVest Asset Management LLC purchased a new stake in shares of Rockwell Medical during the third quarter worth about $279,000. Finally, Vanguard Group Inc. grew its holdings in Rockwell Medical by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after purchasing an additional 43,302 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock. Rockwell Medical Company Profile (Get Free Report) Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
